Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

34.61
-0.7100-2.01%
Volume:557.52K
Turnover:19.32M
Market Cap:2.42B
PE:-11.56
High:35.73
Open:35.31
Low:34.13
Close:35.32
52wk High:38.13
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.86
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:6.93
PE(LYR):-9.93

Loading ...

Pharvaris Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 07

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says

MT Newswires Live
·
Apr 06

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Benzinga_recent_news
·
Apr 06

Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 06

RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 06

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 05

Pharvaris NV expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
Apr 03

Top Premarket Decliners

MT Newswires Live
·
Apr 02

Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data

TIPRANKS
·
Apr 02

Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate

Benzinga Earnings
·
Apr 02

Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share

MT Newswires Live
·
Apr 02

Pharvaris FY25 loss widens to €176 million; Q4 loss climbs to €46.7 million

Reuters
·
Apr 02

Pharvaris Nv - FY2025 Loss €176 Mln; Basic and Diluted Loss per Share €2.97

THOMSON REUTERS
·
Apr 02

Press Release: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Apr 02

Assessing Pharvaris (PHVS) Valuation After Recent Share Price Pullback And Strong Longer Term Returns

Simply Wall St.
·
Mar 29

BioCryst Shares Remain Undervalued, RBC Says

MT Newswires Live
·
Mar 25

Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?

Simply Wall St.
·
Mar 23

Pharvaris announces publications of efficacy, safety evidence on deucrictibant

TIPRANKS
·
Mar 20

Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Reuters
·
Mar 20

Pharvaris NV director Robert Glassman files initial beneficial ownership statement

Reuters
·
Mar 19